Additional capacity has been significantly increased in 2021, building new GMP facilities able to fulfil BSL2 requirements, with about an additional 1000 m2 of net BSL2 GMP laboratory space, now fully operational.
To date, this represents one of the biggest BSL2 facilities among the Eurofins BioPharma Product Testing global network. All facilities are approved to facilitate testing Genetically Modified Microorganisms (GMMO) up to Level 2 and host molecular and cell biology tests, as well as biochemistry analyses.
These facilities include several testing rooms, with negative pressure cascades and H14 HEPA filtration, supporting a wide range of testing. Thanks to the new fully dedicated GMP and GMMO BSL2 facilities, we can support biopharmaceutical companies throughout the biologic lifecycle from analytical method development to marketed product release analysis with drastically increased capacity.
